Q4 Earnings Estimate for VIGL Issued By William Blair

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Equities research analysts at William Blair issued their Q4 2024 earnings per share (EPS) estimates for Vigil Neuroscience in a research report issued to clients and investors on Wednesday, January 8th. William Blair analyst S. Schram forecasts that the company will post earnings per share of ($0.20) for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share. William Blair also issued estimates for Vigil Neuroscience's Q1 2025 earnings at ($0.52) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.59) EPS and Q4 2025 earnings at ($0.64) EPS.

Other research analysts have also issued research reports about the stock. HC Wainwright reissued a "buy" rating and set a $17.00 target price on shares of Vigil Neuroscience in a research report on Friday, November 8th. Wedbush increased their price objective on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the company an "outperform" rating in a report on Friday, November 8th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $19.75.

Vigil Neuroscience Stock Down 2.8 %

Vigil Neuroscience stock traded down $0.05 during mid-day trading on Monday, hitting $1.74. The company's stock had a trading volume of 77,089 shares, compared to its average volume of 209,141. Vigil Neuroscience has a twelve month low of $1.49 and a twelve month high of $6.06. The stock has a market capitalization of $71.13 million, a P/E ratio of -0.84 and a beta of 1.76. The stock's fifty day moving average price is $2.40 and its two-hundred day moving average price is $3.24.

Institutional Trading of Vigil Neuroscience

Several institutional investors and hedge funds have recently made changes to their positions in VIGL. Acadian Asset Management LLC bought a new position in shares of Vigil Neuroscience in the second quarter valued at approximately $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Vigil Neuroscience in the 2nd quarter worth about $87,000. Renaissance Technologies LLC increased its position in shares of Vigil Neuroscience by 19.2% during the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company's stock valued at $286,000 after purchasing an additional 11,536 shares during the last quarter. Walleye Capital LLC increased its holdings in Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company's stock worth $407,000 after acquiring an additional 92,217 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in Vigil Neuroscience in the 3rd quarter worth approximately $442,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.